Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
三葉草生物-B:2023年度報告
Selected announcements | China's non-ferrous mining industry plans to sell up to 163 million shares at a discount of about 13.54%; Longyuan Electric Power's power generation will increase by about 10% during the year
China's net profit for the first quarter was 2,308 billion yuan, up 0.33% year on year; Qiutai Technology sold about 368.39 million mobile phone camera modules in March, up 31.8% from month to month, down 1.7% year on year.
Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial
Clover Biopharmaceuticals (HKG:2197) announced positive preliminary results from the Phase 1 clinical trial of its SCB-1019 vaccine candidate for respiratory syncytial virus (RSV) in Australia, accord
Clover Bio-B (02197.HK) Announces Bivalent RSV Vaccine Candidate SCB-1019 Phase I Clinical Trial Receives Positive Preliminary Data
Gelonghui, April 8, 丨 Clover Bio-B (02197.HK) announced that in the phase I clinical trial of the bivalent RSV PreF-trimer subunit vaccine candidate SCB-1019 developed by the evaluation company based on Clover Biotech's unique Trimer-Tag (protein trimerization) vaccine technology platform, the first batch of young adults obtained positive preliminary immunogenicity and safety data. In the phase I clinical trial, the first group of young adults (ages 18-59) received SCB-1019 or saline placebo on day 0 (before vaccination) and day 28 (vaccination), respectively
Clover Bio-B (02197.HK) grants 9.463 million share options and 7.205 million restricted share units
Glonghui, April 2, 丨 Clover Bio-B (02197.HK) announced that on April 2, 2024, (i) the company granted a total of 9.463 million share options and 7.205 million restricted share units to certain eligible participants in accordance with the terms of the initial public offering after-sales share option plan and the restricted share unit plan, respectively; and (ii) the restricted share unit scheme will only be funded by existing shares and will not be funded by any new shares.
Intraday quick overview | The three major indices rose sharply, the Keji Index rose more than 2%, Bilibili rose nearly 8%, and JD and Meituan rose more than 5%
Biotech stocks rose, with Yao Ming Biotech up more than 6%, Genting Xinyao by more than 5%, Kingsray Biotech by more than 4%, and BeiGene Shenzhou by nearly 2%; Apple concept stocks generally rose, Ruisheng Technology and Gaowei Electronics by about 5%, and Shunyu Optics and Qiutai Technology by about 2%.
Clover Biopharmaceuticals Trims Losses in 2023
Clover Biopharmaceuticals (HKG:2197) posted a loss attributable to the owners of 138.5 million yuan for the year ended Dec. 31, 2023, compared with a loss of 2.45 billion yuan in the previous year, ac
Express News | Clover Biotech: adjusted annual loss of 8.524 million yuan in 2023
Clover Bio-B (02197) released annual results, spent 650 million yuan on R&D, and achieved many important milestones in R&D, production and commercialization
Clover Bio-B (02197) announced results for the year ended December 31, 2023, with revenue of 3925...
CLOVER BIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION
Clover Bio-B (02197.HK) plans to hold a board meeting on March 26 to approve annual results
Glonghui March 14 | Clover Bio-B (02197.HK) announced that the company will hold a board meeting on March 26, 2024 (Tuesday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to evaluate the payment of the final dividend.
CLOVER BIO-B: DATE OF BOARD MEETING
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
A quick overview of the Hong Kong market | The Hang Seng Index rose nearly 2%, and the Science Index rose nearly 3%; insurance, real estate and other sectors were strong throughout the day
Technet stocks were strong. Meituan rose nearly 5%, Bilibili and Kuaishou rose more than 3%, Xiaomi and Jingdong rose more than 2%, Baidu, Ali, and Tencent rose more than 1%, and NetEase followed; insurance stocks were strong throughout the day. China Ping An rose more than 6%, China Life Insurance rose nearly 5%, and AIA Insurance rose more than 2%.
Intraday Overview | The three major indices rose slightly, and the Tech Index rose nearly 2%; auto stocks and biotech stocks rose strongly. NIO rose nearly 8%, and Pharmaceutical Biotech rose more than 9%
Most Technology Network stocks rose, with Station B up more than 4%; Meituan and NetEase up more than 3%; mobile phone equipment stocks showed active performance, with Shunyu Optical Technology up more than 7% and Gaowei Electronics by more than 5%; pharmaceutical distribution stocks improved, Ali Health rose more than 8%, and JD Health rose nearly 5%.
Intraday Overview | The Tech Index fell more than 2%, Apple concept stocks and pharmaceutical stocks had the highest declines, and Shunyu Optical Technology fell more than 8%
Technet stocks collectively weakened, with Xiaomi falling nearly 4%, Meituan falling nearly 3%, and Kuaishou falling more than 2%; domestic housing stocks continued to decline, with Country Garden falling more than 3%; Longhu Group, Xincheng Development, and Sunac China falling nearly 2%; auto stocks were weak, with Zero Sports Auto and NIO falling more than 5%, and Xiaopeng Motors falling more than 4%.
Market Chatter: Sinovac Halts Production of COVID-19 Vaccine as Demand Wanes
Chinese pharmaceutical firm Sinovac Biotech has halted production of its CoronaVac vaccine against COVID-19 amid waning global demand, Yicai Global reported Thursday, citing local media and a document
Hong Kong Stock Concept Tracking | The first and only in China! Nicevir monoclonal antibody was approved in China, and many companies snatched the 10 billion blue ocean (with concept stocks)
On January 2, AstraZeneca and Sanofi jointly announced that the long-acting monoclonal antibody Nirsevimab/nirsevimab (nirsevimab), which was jointly developed by the two companies, was officially approved for marketing by the China Drug Administration to prevent lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants.
Clover Biopharmaceuticals Publishes Positive Results From SCB-219M Clinical Trial
Clover Biopharmaceuticals (HKG:2197) published positive results from the phase I clinical trial on the drug SCB-219M as a treatment of cancer patients with chemotherapy-induced thrombocytopenia. The
No Data